CHINA PHARMA HOLDINGS, INC.CPHIEarnings & Financial Report
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
CPHI Q4 FY2025 Key Financial Metrics
Revenue
$1.2M
Gross Profit
$150.8K
Operating Profit
$-1.2M
Net Profit
$-1.2M
Gross Margin
12.3%
Operating Margin
-97.9%
Net Margin
-99.7%
YoY Growth
8.1%
EPS
$-0.17
CHINA PHARMA HOLDINGS, INC. Q4 FY2025 Financial Summary
CHINA PHARMA HOLDINGS, INC. reported revenue of $1.2M (up 8.1% YoY) for Q4 FY2025, with a net profit of $-1.2M (up 0.2% YoY) (-99.7% margin). Cost of goods sold was $1.1M, operating expenses totaled $1.4M.
Key Financial Metrics
| Total Revenue | $1.2M |
|---|---|
| Net Profit | $-1.2M |
| Gross Margin | 12.3% |
| Operating Margin | -97.9% |
| Report Period | Q4 FY2025 |
CHINA PHARMA HOLDINGS, INC. Annual Revenue by Year
CHINA PHARMA HOLDINGS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.1M).
CHINA PHARMA HOLDINGS, INC. Quarterly Revenue & Net Profit History
CHINA PHARMA HOLDINGS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.2M | +8.1% | $-1.2M | -99.7% |
| Q3 FY2025 | $756.2K | -31.3% | $-651.5K | -86.2% |
| Q2 FY2025 | $1.0M | +10.9% | $-528.4K | -51.5% |
| Q1 FY2025 | $1.1M | -17.0% | $-785.6K | -69.1% |
| Q4 FY2024 | $1.1M | -47.2% | $-1.2M | -108.0% |
| Q3 FY2024 | $1.1M | -39.0% | $-1.1M | -101.6% |
| Q2 FY2024 | $924.9K | -15.8% | $-1.4M | -155.5% |
| Q1 FY2024 | $1.4M | -30.1% | $-955.9K | -69.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $924943 | $1.1M | $1.1M | $1.1M | $1.0M | $756217 | $1.2M |
| YoY Growth | -30.1% | -15.8% | -39.0% | -47.2% | -17.0% | 10.9% | -31.3% | 8.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | $14.3M | $13.5M | $14.9M | $14.2M | $13.8M | $15.8M | $31.0M |
| Liabilities | N/A | $6.9M | $6.9M | $7.1M | $7.2M | $7.3M | $7.5M | $8.3M |
| Equity | $8.3M | $7.4M | $6.5M | $7.7M | $7.0M | $6.5M | $8.3M | $22.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-585158 | $-72726 | $-46952 | $298773 | $-57822 | $291080 | $-236987 | $151990 |